Nanoemulsion enhances α-tocopherol succinate bioavailability in rats

Area of Science:

• Pharmacology
• Nanotechnology
• Oncology

Background:

• Vitamin E analogue α-tocopherol succinate (α-TOS) shows broad anti-tumor effects by inducing apoptosis and targeting mitochondria.
• Low bioavailability of α-TOS presents a significant challenge for formulation development and therapeutic application.
• Developing effective drug delivery systems is crucial for enhancing the efficacy of α-TOS.

Purpose of the Study:

• To develop and evaluate α-tocopherol succinate nanoemulsion (α-TOS-NE) as a novel drug delivery system for α-TOS.
• To assess the in vitro anticancer efficacy and in vivo bioavailability of α-TOS-NE compared to free α-TOS.
• To determine the potential of α-TOS-NE for intravenous (I.V.) administration.

Main Methods:

• Cytotoxicity was evaluated using MTT assays on MCF-7 and KB cancer cell lines.
• Mitochondrial membrane potential (ΔΨ) was measured to assess cellular effects.
• Pharmacokinetic profiles were analyzed for intravenous (I.V.) and intraperitoneal (I.P.) administration of α-TOS-NE and I.P. administration of free α-TOS.

Main Results:

• α-TOS-NE exhibited significantly stronger cytotoxicity and a greater decrease in ΔΨ compared to free α-TOS in vitro.
• Nanoemulsion (NE) formulation enabled I.V. administration of α-TOS, creating a potential I.V. preparation.
• I.P. administration of α-TOS-NE resulted in higher bioavailability than I.P. administration of free α-TOS in rats.

Conclusions:

• Nanoemulsion formulation significantly enhances the anti-cancer efficacy and in vivo bioavailability of α-TOS.
• The developed α-TOS-NE is a safe and promising drug delivery system for potential clinical trials, particularly for I.V. administration.
• α-TOS-NE represents a viable strategy to improve the therapeutic potential of α-tocopherol succinate.